Shionogi's Earnings Likely to Be Driven by HIV Royalties — Market Talk

Shionogi's earnings are likely to be driven by HIV royalties, Jefferies analysts say in a note. Given that its joint-venture partner GSK has raised its HIV sales guidance, the U.S. bank expects the trend of strong HIV royalties to continue throughout the fiscal year. Over the medium- to long-term…